Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VENOX
- Development stage
- Unknown
- Lead developer
- Inmunotek
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
VENOX is an allergy vaccine developed by Inmunotek S.L. It is indicated for the treatment of Hymenoptera venom allergy, specifically targeting venoms from Vespula spp. (wasp) and Apis mellifera (bee). The vaccine is used in immunotherapy to induce tolerance and reduce the severity of allergic reactions to stings in real-life conditions.
- Brand names
- VENOX
02
Targets
IgE (Immunoglobulin E)Honey bee venom allergens
Beyond the preview
Go deeper on VENOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VENOX.